Effect of a novel oral chemotherapeutic agent containing a combination of trifluridine, tipiracil and the novel triple angiokinase inhibitor nintedanib, on human colorectal cancer xenografts

Suzuki,Norihiko; Nakagawa,Fumio; Matsuoka,Kazuaki; Takechi,Teiji

doi:10.3892/or.2016.5208

Effect of a novel oral chemotherapeutic agent containing a combination of trifluridine, tipiracil and the novel triple angiokinase inhibitor nintedanib, on human colorectal cancer xenografts

Authors:
- Norihiko Suzuki
- Fumio Nakagawa
- Kazuaki Matsuoka
- Teiji Takechi
View Affiliations

Affiliations: Translational Research Laboratory, Taiho Pharmaceutical Co., Ltd., Tokushima City, Tokushima 771-0194, Japan, Applied Pharmacology Laboratory, Tokushima Research Center, Taiho Pharmaceutical Co., Ltd., Tokushima City, Tokushima 771-0194, Japan
Published online on: October 27, 2016 https://doi.org/10.3892/or.2016.5208
Pages: 3123-3130
Copyright: © Suzuki et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Trifluridine/tipiracil (TFTD) is a combination drug that is used for the treatment of metastatic colorectal cancer and was formerly known as TAS-102. It is a combination of two active pharmaceutical compounds, trifluridine, an antineoplastic thymidine-based nucleoside analog, and tipiracil, which enhances the bioavailability of trifluridine in vivo. TFTD is used for the treatment of patients with unresectable advanced or recurrent colorectal cancer that is resistant to standard therapies. In the present study, the anticancer effects of trifluridine in combination with nintedanib, an oral triple angiokinase inhibitor, on human colorectal cancer cell lines were investigated. The cytotoxicity against DLD-1, HT-29, and HCT116 cell lines was determined by the crystal violet staining method. The combination of trifluridine and nintedanib exerted an additive effect on the growth inhibition of DLD-1 and HT-29 cells and a sub-additive effect on HCT116 cells, as determined by isobologram analyses. Subsequently, the human colorectal cancer cell lines were implanted subcutaneously into nude mice to allow the evaluation of the in vivo tumor growth inhibitory effects of TFTD and nintedanib combination therapy. TFTD (150 mg/kg/day) and/or nintedanib (40 mg/kg/day) were orally administered to the mice twice daily from day 1 to day 14. The tumor growth inhibition with combination therapy was 61.5, 72.8, 67.6 and 67.5% for the DLD-1, DLD-1/5-FU, HT-29, and HCT116 xenografts, respectively. This was significantly (P<0.05) higher than the effects of monotherapy with either TFTD or nintedanib. These results demonstrated the effectiveness of the combination of TFTD and nintedanib in the treatment of colorectal cancer xenografts. The concentration of trifluridine incorporated into DNA in the HT-29 and HCT116 tumors was determined by liquid chromatography-tandem mass spectrometry. The incorporation levels following treatment with TFTD and nintedanib for 14 consecutive days were higher than those associated with TFTD treatment alone. The preclinical findings indicate that the combination therapy with TFTD and nintedanib is a promising treatment option for colorectal cancer.

View Figures

View References

1	Heidelberger C, Birnie GD, Boohar J and Wentland D: Fluorinated pyrimidines. XX. Inhibition of the nucleoside phosphorylase cleavage of 5-fluoro-2′-deoxyuridine by 5-trifluoromethyl-2′-deoxyuridine. Biochim Biophys Acta. 76:315–318. 1963. View Article : Google Scholar : PubMed/NCBI
2	Gottschling H and Heidelberger C: Fluorinated pyrimidines. XIX some biological effects of 5-trifluoromthyluracil and 5-trifluoromethyl-2′-deoxyuridine of Escherichia coli and bacteriophage T4G. J Mol Biol. 7:541–560. 1963. View Article : Google Scholar : PubMed/NCBI
3	Reyes P and Heidelberger C: Fluorinated pyrimidines. XXVI. Mammalian thymidylate synthetase: Its mechanism of action and inhibition by fluorinated nucleotides. Mol Pharmacol. 1:14–30. 1965.PubMed/NCBI
4	Fujiwara Y, Oki T and Heidelberger C: Fluorinated pyrimidines. XXXVII. Effects of 5-trifluoromethyl-2′-deoxyuridine on the synthesis of deoxyribonucleic acid of mammalian cells in culture. Mol Pharmacol. 6:273–280. 1970.PubMed/NCBI
5	Fukushima M, Suzuki N, Emura T, Yano S, Kazuno H, Tada Y, Yamada Y and Asao T: Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2′-deoxyribonucleosides. Biochem Pharmacol. 59:1227–1236. 2000. View Article : Google Scholar : PubMed/NCBI
6	Emura T, Suzuki N, Yamaguchi M, Ohshimo H and Fukushima M: A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. Int J Oncol. 25:571–578. 2004.PubMed/NCBI
7	Lenz HJ, Stintzing S and Loupakis F: TAS-102, a novel antitumor agent: A review of the mechanism of action. Cancer Treat Rev. 41:777–783. 2015. View Article : Google Scholar : PubMed/NCBI
8	Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H, Tsuji A, Yamaguchi K, Muro K, Sugimoto N, et al: TAS-102 monotherapy for pretreated metastatic colorectal cancer: A double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 13:993–1001. 2012. View Article : Google Scholar : PubMed/NCBI
9	Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, et al: RECOURSE Study Group: Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 372:1909–1919. 2015. View Article : Google Scholar : PubMed/NCBI
10	Al-Husein B, Abdalla M, Trepte M, Deremer DL and Somanath PR: Antiangiogenic therapy for cancer: An update. Pharmacotherapy. 32:1095–1111. 2012. View Article : Google Scholar : PubMed/NCBI
11	Moreira IS, Fernandes PA and Ramos MJ: Vascular endothelial growth factor (VEGF) inhibition - a critical review. Anticancer Agents Med Chem. 7:223–245. 2007. View Article : Google Scholar : PubMed/NCBI
12	Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, et al: Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol. 26:3743–3748. 2008. View Article : Google Scholar : PubMed/NCBI
13	Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG and Kerbel RS: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 15:232–239. 2009. View Article : Google Scholar : PubMed/NCBI
14	Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, et al: BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 68:4774–4782. 2008. View Article : Google Scholar : PubMed/NCBI
15	Bouche O, Maindrault-Goebel F, Ducreux M, Lledo G, Andre T, Stopfer P, Amellal N, Merger M and De Gramont A: Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer. Anticancer Res. 31:2271–2281. 2011.PubMed/NCBI
16	Van Cutsem E, Prenen H, D'Haens G, Bennouna J, Carrato A, Ducreux M, Bouché O, Sobrero A, Latini L, Staines H, et al: A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients. Ann Oncol. 26:2085–2091. 2015. View Article : Google Scholar : PubMed/NCBI
17	Awasthi N and Schwarz RE: Profile of nintedanib in the treatment of solid tumors: The evidence to date. Onco Targets Ther. 8:3691–3701. 2015. View Article : Google Scholar : PubMed/NCBI
18	Nukatsuka M, Nakagawa F, Saito H, Sakata M, Uchida J and Takechi T: Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts. Anticancer Res. 35:1437–1445. 2015.PubMed/NCBI
19	Nukatsuka M, Nakagawa F and Takechi T: Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with oxaliplatin on human colorectal and gastric cancer xenografts. Anticancer Res. 35:4605–4615. 2015.PubMed/NCBI
20	Tsukihara H, Nakagawa F, Sakamoto K, Ishida K, Tanaka N, Okabe H, Uchida J, Matsuo K and Takechi T: Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts. Oncol Rep. 33:2135–2142. 2015.PubMed/NCBI
21	Murakami Y, Kazuno H, Emura T, Tsujimoto H, Suzuki N and Fukushima M: Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. Int J Oncol. 17:277–283. 2000.PubMed/NCBI
22	Saotome K, Morita H and Umeda M: Cytotoxicity test with simplified crystal violet staining method using microtitre plates and its application to injection drugs. Toxicol In Vitro. 3:317–321. 1989. View Article : Google Scholar : PubMed/NCBI
23	Chou TC and Talalay P: Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem. 115:207–216. 1981. View Article : Google Scholar : PubMed/NCBI
24	Kudo K, Arao T, Tanaka K, Nagai T, Furuta K, Sakai K, Kaneda H, Matsumoto K, Tamura D, Aomatsu K, et al: Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2⁺pTyr⁺ peripheral blood leukocytes as a pharmacodynamic biomarker in vivo. Clin Cancer Res. 17:1373–1381. 2011. View Article : Google Scholar : PubMed/NCBI
25	Suzuki N, Nakagawa F, Nukatsuka M and Fukushima M: Trifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaks. Exp Ther Med. 2:393–397. 2011.PubMed/NCBI
26	Tanaka N, Sakamoto K, Okabe H, Fujioka A, Yamamura K, Nakagawa F, Nagase H, Yokogawa T, Oguchi K, Ishida K, et al: Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol Rep. 32:2319–2326. 2014.PubMed/NCBI
27	Bauer P, Röhmel J, Maurer W and Hothorn L: Testing strategies in multi-dose experiments including active control. Stat Med. 17:2133–2146. 1998. View Article : Google Scholar : PubMed/NCBI
28	Suzuki N, Emura T and Fukushima M: Mode of action of trifluorothymidine (TFT) against DNA replication and repair enzymes. Int J Oncol. 39:263–270. 2011.PubMed/NCBI
29	Markley JC, Chirakul P, Sologub D and Sigurdsson ST: Incorporation of 2′-deoxy-5-(trifluoromethyl)uridine and 5-cyano-2′-deoxyuridine into DNA. Bioorg Med Chem Lett. 11:2453–2455. 2001. View Article : Google Scholar : PubMed/NCBI
30	Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med. 7:987–989. 2001. View Article : Google Scholar : PubMed/NCBI
31	Heldin CH, Rubin K, Pietras K and Ostman A: High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer. 4:806–813. 2004. View Article : Google Scholar : PubMed/NCBI
32	Mésange P, Poindessous V, Sabbah M, Escargueil AE, de Gramont A and Larsen AK: Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor. Oncotarget. 5:4709–4721. 2014. View Article : Google Scholar : PubMed/NCBI
33	Ioannou M, Paraskeva E, Baxevanidou K, Simos G, Papamichali R, Papacharalambous C, Samara M and Koukoulis G: HIF-1α in colorectal carcinoma: Review of the literature. J BUON. 20:680–689. 2015.PubMed/NCBI
34	Shimomura M, Hinoi T, Kuroda S, Adachi T, Kawaguchi Y, Sasada T, Takakura Y, Egi H, Okajima M, Tashiro H, et al: Overexpression of hypoxia inducible factor-1 alpha is an independent risk factor for recurrence after curative resection of colorectal liver metastases. Ann Surg Oncol. 20:(Suppl 3). S527–S536. 2013. View Article : Google Scholar : PubMed/NCBI